Patients' characteristics and results
Characteristic . | Result . |
|---|---|
| No. of patients | 18 |
| Median age, y (range) | 53 (31-64) |
| Deletion 13* | |
| Positive, no. | 6 |
| Negative, no. | 9 |
| Unknown, no. | 3 |
| Previous HD chemotherapy with autologous SCT | |
| 1 autograft, no. | 12 |
| 2 autografts, no. | 5 |
| Allogeneic SCT, no. | 18 |
| Conditioning | |
| Reduced-intensity conditioning, no. | 17 |
| Standard conditioning, no. | 1 |
| Donor | |
| MUD, no. | 9 |
| Related, no. | 9 |
| Prior DLI, no. | 12 |
| Prior thalidomide treatment, no. | 3 |
| Inclusion for thalidomide and DLI | |
| Progressive disease, no. | 9 |
| Residual disease, no. | 9 |
| Median interval between thalidomide and DLI, d (range) | 15 (13-74) |
| Median interval between allograft and thalidomide, mo (range) | 12 (4-47) |
| Response to thalidomide/DLI | |
| CR, no. (%) | 4 (22) |
| PR, no. (%) | 5 (28) |
| MR, no. (%) | 3 (17) |
| SD, no. (%) | 5 (28) |
| PD, no. (%) | 1 (5) |
| Median follow-up, mo (range) | 12 (4-28) |
| 2-year estimated overall survival, % | 100 |
| 2-year estimated progression-free survival, % (95% CI) | 84 (62-100) |
Characteristic . | Result . |
|---|---|
| No. of patients | 18 |
| Median age, y (range) | 53 (31-64) |
| Deletion 13* | |
| Positive, no. | 6 |
| Negative, no. | 9 |
| Unknown, no. | 3 |
| Previous HD chemotherapy with autologous SCT | |
| 1 autograft, no. | 12 |
| 2 autografts, no. | 5 |
| Allogeneic SCT, no. | 18 |
| Conditioning | |
| Reduced-intensity conditioning, no. | 17 |
| Standard conditioning, no. | 1 |
| Donor | |
| MUD, no. | 9 |
| Related, no. | 9 |
| Prior DLI, no. | 12 |
| Prior thalidomide treatment, no. | 3 |
| Inclusion for thalidomide and DLI | |
| Progressive disease, no. | 9 |
| Residual disease, no. | 9 |
| Median interval between thalidomide and DLI, d (range) | 15 (13-74) |
| Median interval between allograft and thalidomide, mo (range) | 12 (4-47) |
| Response to thalidomide/DLI | |
| CR, no. (%) | 4 (22) |
| PR, no. (%) | 5 (28) |
| MR, no. (%) | 3 (17) |
| SD, no. (%) | 5 (28) |
| PD, no. (%) | 1 (5) |
| Median follow-up, mo (range) | 12 (4-28) |
| 2-year estimated overall survival, % | 100 |
| 2-year estimated progression-free survival, % (95% CI) | 84 (62-100) |
HD indicates high dose; MUD, matched unrelated donor.
Detected by fluorescence in situ hybridization (FISH).